ADRA2C; ADRA2A; GPBAR1; DRD4; | |
NPSR1; CXCR1; NMUR2; | |
RECQL; PLA2G1B; PIK3R1; GLO1; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; HSD11B1; AKR1B10; ALDH1A1; ALOX12; GFER; NOX4; PYGL; POLB; | |
PTPN1; PTPRF; PTPN2; ACP1; | |
ACHE; GAA; | |
AKT1; MET; CAMK2B; CSNK2A1; DAPK1; AXL; NEK2; FLT3; NEK6; PKN1; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; KDR; | |
CA12; CA9; CA5B; CA3; CA14; CA7; CA5A; CA4; CA6; CA2; CA1; | |
NR1H4; | |
RORC; | |
ESR2; | |
KDM4E; | |
MAOA; ALOX5; XDH; | |
CASP7; CASP1; | |
MMP13; MMP3; MMP2; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCG2; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.157E-10 | 2.198E-07 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, GLO1, MMP13, MMP2, MMP3, MMP9, NR1H4, PTPN1, RORC, TP53 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.643E-10 | 2.642E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.365E-09 | 4.328E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.391E-09 | 4.328E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.324E-09 | 8.826E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 7.543E-09 | 1.747E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, SRC |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.913E-08 | 3.893E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 6.893E-08 | 1.146E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 7.029E-08 | 1.151E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.657E-08 | 1.300E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
CC | GO:0016020; membrane | GO:0005886; plasma membrane | 1.439E-07 | 2.076E-05 | ABCC1, ABCG2, ACHE, ACP1, ADRA2A, ADRA2C, AKT1, ALK, ALOX12, ALOX15, AXL, BACE1, CA12, CA14, CA2, CA4, CA9, CAMK2B, CSNK2A1, CXCR1, DAPK1, DRD4, FLT3, GAA, GLO1, GPBAR1, GSK3B, HSD17B10, IGF1R, KDR, MAPK1, MET, MMP2, NMUR2, NPSR1, PIK3R1, PIM1, PKN1, PTK2, PTPN1, PTPN2, PTPRF, SRC |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.865E-07 | 3.759E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.770E-07 | 4.664E-05 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 7.092E-07 | 8.302E-05 | ADRA2A, AKT1, HIF1A, NOX4, NR1H4, PIK3R1, PTPN2, PYGL |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 7.517E-07 | 8.753E-05 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.653E-07 | 9.970E-05 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, ALK, CAMK2B, CASP1, CSNK2A1, DAPK1, DRD4, ESR2, FLT3, IGF1R, KDR, MAPK1, MET, MMP9, NFKB1, PYGL, STAT6, TP53, XDH |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.393E-07 | 1.054E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 9.892E-07 | 1.105E-04 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.818E-06 | 1.950E-04 | ADRA2A, AURKB, CA2, CA7, HIF1A, KDR, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B, SRC |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.872E-06 | 1.989E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.374E-06 | 2.404E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 3.013E-06 | 2.929E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 4.367E-06 | 4.135E-04 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1 |
BP | GO:0051179; localization | GO:0046903; secretion | 4.896E-06 | 4.601E-04 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, GAA, HIF1A, MAPK1, MMP9, MPO, NFKB1, NMUR2, NR1H4, PLA2G1B, PYGL, XDH |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.918E-06 | 4.601E-04 | AKT1, CASP7, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, RORC, SRC |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 5.208E-06 | 4.785E-04 | ADRA2A, ADRA2C, DRD4 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 5.302E-06 | 4.851E-04 | AKT1, CA5A, CA5B, CASP1, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, SRC, TP53 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 7.785E-06 | 6.754E-04 | NR1H4, PLA2G1B, PYGL |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 9.000E-06 | 7.632E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 9.000E-06 | 7.632E-04 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 9.514E-06 | 7.998E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.138E-05 | 9.305E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.205E-05 | 9.680E-04 | AKT1, CYP1A2, MAPK1, MMP9 |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.379E-05 | 1.080E-03 | ADRA2A, AKT1, CASP1, CASP7, CDK1, DAPK1, GSK3B, PTK2, SRC, XDH |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.538E-05 | 1.175E-03 | AKT1, HIF1A, NFKB1, PTPN2, SRC |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.757E-05 | 1.315E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.019E-05 | 1.480E-03 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.019E-05 | 1.480E-03 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 2.034E-05 | 1.481E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.099E-05 | 1.509E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.099E-05 | 1.509E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 2.143E-05 | 1.530E-03 | ACHE, AKR1B10, AKT1, ALDH1A1, AURKB, BACE1, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GAA, GSK3B, HSD17B10, MAOA, PLA2G1B, PYGL, TP53, XDH |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.176E-05 | 1.548E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.207E-05 | 1.565E-03 | AKT1, CASP1, CASP7, CYP1B1, DAPK1, GSK3B, MMP9, NOX4, PTPN2, SRC, TP53, XDH |
BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 2.325E-05 | 1.644E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 2.616E-05 | 1.791E-03 | PIK3R1, PTPN1, PTPN2 |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 2.757E-05 | 1.871E-03 | AKT1, CASP1, CASP7, PTK2 |
CC | GO:0043226; organelle | GO:0043227; membrane-bounded organelle | 2.803E-05 | 1.896E-03 | ABCC1, ABCG2, ACHE, ACP1, ADRA2C, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALK, ALOX12, AURKB, AXL, BACE1, CA1, CA2, CA4, CA5A, CA5B, CA6, CASP1, CASP7, CDK1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, ESR2, FLT3, GAA, GFER, GLO1, GSK3B, HIF1A, HSD17B10, IGF1R, KDM4E, KDR, LMNA, MAOA, MAPK1, MMP2, MMP9, MPO, NEK6, NFKB1, NOX4, NUAK1, PIK3R1, PIM1, PKN1, PLA2G1B, POLB, PTK2, PTPN1, PTPN2, PTPRF, PYGL, RECQL, RORC, SRC, TP53, XDH |
CC | GO:0044464; cell part | GO:0005829; cytosol | 4.122E-05 | 2.671E-03 | ACP1, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CSNK2A1, FLT3, GFER, GLO1, GSK3B, HIF1A, LMNA, MAPK1, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PTPN1, PTPN2, PYGL, SRC, STAT6, TP53, XDH |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.813E-05 | 3.064E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 4.965E-05 | 3.143E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.070E-05 | 3.200E-03 | ALOX12, ALOX15, ALOX5 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 5.431E-05 | 3.398E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.136E-05 | 3.774E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 6.136E-05 | 3.774E-03 | AURKB, CDK1, PKN1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.279E-05 | 3.776E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.279E-05 | 3.776E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.279E-05 | 3.776E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.279E-05 | 3.776E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.279E-05 | 3.776E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.279E-05 | 3.776E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.279E-05 | 3.776E-03 | GPBAR1, NR1H4 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.456E-05 | 3.862E-03 | IGF1R, KDR, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 7.300E-05 | 4.285E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 7.482E-05 | 4.368E-03 | AKT1, ALK, CYP1B1, ESR2, MAPK1, NFKB1, NR1H4, PIM1, PLA2G1B |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 7.751E-05 | 4.501E-03 | AKT1, HIF1A, MMP9, PTPN1, SRC |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 8.576E-05 | 4.901E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, KDR, PTK2, PTPN1 |
BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 1.117E-04 | 6.268E-03 | AKT1, GAA, GSK3B, PYGL |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.138E-04 | 6.369E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.184E-04 | 6.595E-03 | CYP1A1, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.191E-04 | 6.616E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 1.196E-04 | 6.616E-03 | AKR1B1, AKT1, HSD17B2, KDR, MMP2, NR1H4, SRC, TP53 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.226E-04 | 6.726E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB |
BP | GO:0002376; immune system process | GO:0045321; leukocyte activation | 1.240E-04 | 6.748E-03 | ALOX5, AXL, CXCR1, FLT3, GAA, MAPK1, MMP9, MPO, NFKB1, PIK3R1, PTPN2, PYGL, RORC |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.252E-04 | 6.748E-03 | NMUR2, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.252E-04 | 6.748E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.252E-04 | 6.748E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.252E-04 | 6.748E-03 | PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.252E-04 | 6.748E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0030971; receptor tyrosine kinase binding | 1.288E-04 | 6.925E-03 | PIK3R1, PTPN1, PTPN2, TP53 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.423E-04 | 7.594E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 1.566E-04 | 8.239E-03 | DRD4, NMUR2, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.566E-04 | 8.239E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.767E-04 | 9.098E-03 | ABCG2, CA12, CA2, CA7, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53 |
BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 1.784E-04 | 9.142E-03 | CYP19A1, CYP1B1, HSD17B2 |
BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.899E-04 | 9.709E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.408E-23 | 1.533E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.102E-17 | 3.093E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.901E-16 | 1.836E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.645E-23 | 1.582E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.898E-12 | 5.397E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.321E-09 | 1.062E-07 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MAPK1; MET; TP53 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.323E-09 | 8.071E-08 | PTPN1; CSNK2A1; SRC; MAPK1; ACP1; MET; PTPRF; IGF1R |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.798E-09 | 2.488E-07 | HSD11B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.904E-08 | 5.806E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.167E-08 | 7.245E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; ESR2 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.597E-08 | 6.789E-07 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.888E-08 | 1.807E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.394E-07 | 2.125E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.191E-07 | 1.981E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.086E-07 | 1.981E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.363E-07 | 3.239E-06 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.852E-07 | 3.036E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.896E-07 | 3.036E-06 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.980E-07 | 2.588E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.905E-07 | 3.036E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; ESR2 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.986E-07 | 3.036E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.380E-07 | 3.817E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.811E-07 | 3.487E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.969E-07 | 4.750E-06 | CASP7; MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.610E-07 | 4.666E-06 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; NFKB1; PTPRF |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.731E-06 | 1.142E-05 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; HSD11B1; CYP2C8; AKR1B10; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.610E-07 | 7.035E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.077E-06 | 7.577E-06 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.434E-07 | 5.668E-06 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.861E-06 | 1.174E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.025E-06 | 1.786E-05 | CASP7; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.700E-07 | 2.393E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.884E-06 | 1.759E-05 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL; PTPRF |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.913E-06 | 3.182E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.804E-06 | 4.080E-05 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.748E-06 | 1.142E-05 | HSD11B1; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.073E-05 | 5.018E-05 | CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.976E-06 | 2.759E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.433E-06 | 1.963E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.593E-05 | 6.941E-05 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.306E-05 | 1.235E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.632E-05 | 1.329E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.855E-05 | 1.136E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 3.238E-05 | 1.234E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.254E-06 | 4.082E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.363E-05 | 1.535E-04 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.124E-05 | 5.018E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.364E-05 | 1.852E-04 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.254E-06 | 4.082E-05 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.844E-05 | 7.498E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.844E-05 | 7.498E-05 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.043E-05 | 5.018E-05 | CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.124E-05 | 5.018E-05 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.313E-04 | 4.214E-04 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 7.639E-05 | 2.542E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.378E-04 | 4.347E-04 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.844E-05 | 7.498E-05 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 6.262E-05 | 2.122E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.085E-05 | 1.466E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.013E-04 | 3.311E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.836E-04 | 5.599E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.779E-04 | 7.947E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 5.723E-04 | 1.496E-03 | GSK3B; CASP7; AKT1; PIK3R1; NFKB1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 4.325E-04 | 1.147E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 7.028E-04 | 1.786E-03 | PIM1; AKT1; STAT6; PIK3R1; PTPN2 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 9.017E-04 | 2.230E-03 | AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.034E-03 | 2.456E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 9.261E-04 | 2.260E-03 | BACE1; GSK3B; CASP7; MAPK1; HSD17B10 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.198E-03 | 2.746E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 9.623E-04 | 2.317E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.958E-03 | 4.266E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.290E-04 | 1.827E-03 | CAMK2B; SRC; MMP2; MAPK1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.077E-03 | 2.526E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.288E-03 | 2.910E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.158E-03 | 4.592E-03 | SRC; AKT1; MAPK1; PIK3R1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.477E-04 | 4.581E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.200E-03 | 2.746E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.911E-03 | 4.213E-03 | MMP2; PIK3R1; MMP9; PTK2 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 6.014E-03 | 1.101E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 4.065E-04 | 1.094E-03 | SRC; PIK3R1; MET; PTK2 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.223E-03 | 4.676E-03 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.871E-03 | 5.903E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.401E-04 | 7.086E-04 | CXCR1; SRC; MET; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 5.891E-04 | 1.518E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.950E-03 | 5.932E-03 | AKT1; MAPK1; PIK3R1; IGF1R |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.497E-03 | 5.192E-03 | GSK3B; MAPK1; MET; PTK2 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.730E-03 | 7.185E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.920E-03 | 7.473E-03 | CXCR1; AKT1; MAPK1; PIK3R1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.540E-04 | 7.378E-04 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 4.321E-03 | 8.152E-03 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.442E-03 | 1.006E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.499E-04 | 9.558E-04 | CASP7; CASP1; MAPK1; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.835E-04 | 7.983E-04 | CA2; NR1H4; CYP3A4; ABCG2 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.398E-03 | 1.638E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.535E-02 | 2.530E-02 | SRC; MAPK1; PIK3R1; PTK2 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 3.064E-02 | 4.415E-02 | CXCR1; FLT3; KDR; MET |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.713E-02 | 4.004E-02 | AKT1; MAPK1; TP53; NFKB1 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.520E-02 | 4.955E-02 | NMUR2; ADRA2C; ADRA2A; DRD4 |
hsa04530 | Tight junction_Homo sapiens_hsa04530 | 2.418E-02 | 3.687E-02 | CSNK2A1; SRC; AKT1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.795E-02 | 2.831E-02 | GSK3B; CDK1; TP53 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.795E-02 | 2.831E-02 | AKT1; PIK3R1; IGF1R |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.010E-02 | 1.727E-02 | CAMK2B; GSK3B; MAPK1 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.037E-02 | 1.758E-02 | CAMK2B; AKT1; PYGL |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 8.285E-03 | 1.472E-02 | AKT1; MAPK1; PIK3R1 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.010E-02 | 1.727E-02 | PIK3R1; NFKB1; PTK2 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 7.118E-03 | 1.290E-02 | SRC; CDK1; MAPK1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.962E-05 | 1.153E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 3.465E-03 | 6.745E-03 | AKT1; MAPK1; PIK3R1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.917E-03 | 5.932E-03 | AKT1; PIK3R1; IGF1R |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 3.494E-02 | 4.955E-02 | CAMK2B; MAPK1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.049E-03 | 5.999E-03 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 3.049E-03 | 5.999E-03 | RORC; STAT6; NFKB1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.891E-03 | 4.213E-03 | CASP7; CASP1; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.095E-03 | 4.511E-03 | CASP1; MAPK1; NFKB1 |
hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 3.303E-02 | 4.722E-02 | CASP1; NFKB1 |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.933E-02 | 4.260E-02 | MAPK1; IGF1R |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.581E-02 | 3.840E-02 | AKT1; PIK3R1 |
hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.843E-02 | 4.163E-02 | AKR1B10; AKR1B1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.496E-02 | 3.775E-02 | GSK3B; TP53 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 2.581E-02 | 3.840E-02 | GAA; PYGL |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 2.168E-02 | 3.334E-02 | CASP1; TP53 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.011E-02 | 3.119E-02 | MAOA; NFKB1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.934E-02 | 3.026E-02 | MAPK1; PIK3R1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.712E-02 | 2.773E-02 | AKT1; PIK3R1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.785E-02 | 2.831E-02 | CYP3A4; XDH |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.641E-02 | 2.681E-02 | ABCC1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.304E-02 | 2.169E-02 | MAPK1; PIK3R1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.170E-04 | 8.790E-04 | AKR1B10; GAA; AKR1B1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.353E-03 | 1.319E-02 | MAPK1; TP53 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 8.905E-03 | 1.567E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.118E-02 | 1.877E-02 | AKR1B10; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.662E-03 | 8.705E-03 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.941E-04 | 5.823E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
NA: NA | Upper abdominal bloating | NA | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; ADRA2C |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Cancer | C00-C96 | CA9; AKT1; MET; CSNK2A1; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TP53; CA1; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; FLT3; FLT3; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
NA: NA | GIST | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
C00-D49: Neoplasms | Glioma | C71 | KDR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; HSD11B1; HSD11B1; PTPN1; GSK3B |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; ADRA2C |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; CASP1; MMP3 |
C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; ACHE; ACHE; ACHE; GSK3B; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; NFKB1; GPBAR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |